Clinical trials: Prostatic Hypertrophy, Benign
Benign Prostate Enlargement
Electromagnetic Field Therapy Versus Aerobic Exercise on Prostatic Function in Elderly With Benign Prostatic Hyperplasia
This study will be carried out on seventy five elderly patients with benign prostatic hyperplasia. Their age will range from 60 to 75 years old.
- Trial name
- NCT07357168
- Testing
- pulsed electromagnetic field, Treadmill machine
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Cairo University
Benign Prostatic Hyperplasia
Prostate Bipolar Enucleation and Resection Versus Open Prostatectomy
Benign prostatic hyperplasia (BPH) is a frequent disease in aging men accompanied by bladder outlet obstruction (BOO). Open prostatectomy (OP) is still considered the first-line treatment for more than 80 ml prostate size.
- Trial name
- NCT05416606
- Testing
- transurethral bipolar enucleation and resection of the prostate, open surgical transvesical prostatectomy
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Helwan University
Benign Prostatic Hypertrophy
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical study is designed to demonstrate that the newly adopted dose is not inferior to the existing dose in its efficacy and safety.
- Trial name
- NCT01260129
- Testing
- Silodosin
- Where
- 14 sites in South Korea
- Volunteers
- 424 people
- Sponsor
- JW Pharmaceutical
Benign Prostate Hyperplasia
Changes of the Hemodynamic Profiles on Bio Reactance Technique During TURP in Elderly Patients
The purpose of this study is to evaluate the change of the hemodynamic profiles on bio reactance technique during TURP in elderly patients.
- Trial name
- NCT02483819
- Volunteers
- 20 people
- Sponsor
- Yonsei University
Prostatic Hyperplasia
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) at 12 months post prostatic artery embolization (PAE) with…
- Trial name
- NCT03179228
- Testing
- Prostate Embolization
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- John D Louie
Benign Prostatic Hyperplasia
Comparative Outcomes of Rezūm Versus EchoLaser for Treatment of Benign Prostatic Hyperplasia With Enlarged Median Lobe.
This study evaluates and compares two minimally invasive surgical therapies for treating men with benign prostatic hyperplasia (BPH) who specifically have an enlarged median lobe.
- Trial name
- NCT07578428
- Testing
- Rezūm Water Vapor Thermal Therapy, EchoLaser Transperineal Laser Ablation (TPLA)
- Volunteers
- 80 people
- Sponsor
- Benha University
Benign Prostatic Hyperplasia
Ultrasound-Guided Photoselective Vaporization of the Prostate
Benign prostatic hyperplasia (BPH) is a major cause of lower urinary tract symptoms (LUTS) affecting aging men. Medical therapy for BPH includes alpha adrenergic blockers and 5α-reductase inhibitors.
- Trial name
- NCT02346500
- Testing
- Transrectal Ultrasound
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)
This study is for individuals electing to have GreenLight Photoselective Vaporization of the Prostate (PVP) to treat symptoms from an enlarged prostate gland.
- Trial name
- NCT00274417
- Testing
- dutasteride
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Urology of Virginia
Acute Urinary Retention, Benign Prostatic Hyperplasia
Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention
This randomized controlled trial will compare three medication strategies before trial without catheter in men with acute urinary retention due to benign prostatic hyperplasia who were already taking tamsulosin 0.4 mg once daily…
- Trial name
- NCT07650968
- Testing
- Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg
- Where
- Egypt
- Volunteers
- 378 people
- Sponsor
- Beni-Suef University
Atherosclerotic Cardiovascular Disease (ASCVD), Benign Prostatic Hypertrophy (BPH)
Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies
To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).
- Trial name
- NCT07196280
- Testing
- 5-Alpha Reductase Inhibitors
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Healthy People, Benign Prostatic Hyperplasia
The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis
Prostate-specific antigen (PSA) testing has limited specificity for prostate cancer diagnosis, leading to a high rate of unnecessary biopsies.
- Conditions
- Healthy People, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06589154
- Testing
- Multi-modal artificial intelligence model (BEAM)
- Where
- 10 sites in China
- Volunteers
- 1,651 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
BPH
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.
- Trial name
- MT-06 (NCT03395522)
- Testing
- iTind
- Where
- 12 sites in Australia, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Medi-Tate Ltd.
Enlarged Prostate With Lower Urinary Tract Symptoms
Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
The main objective of this prospective randomized controlled study is to compare safety and efficacy of Vardenafil versus Tadalafil versus Tamsulosin in terms of (voiding function, sexual function and quality of life) in the…
- Trial name
- NCT06491108
- Testing
- Vardenafil 5 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Benign Prostate Hypertrophy(BPH), LUTS(Lower Urinary Tract Symptoms)
MISTER Study: Minimally Invasive Steam Therapy - Russian Effectiveness Registry
Rezūm is a minimally invasive procedure that uses water vapor (steam) to treat urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia, BPH).
- Trial name
- MISTER (NCT07723378)
- Testing
- Rezūm
- Where
- Russia
- Volunteers
- 1,400 people
- Sponsor
- Sechenov University
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
To compare between efficacy of phosphodiesterase5 inhibitors (tadalafil 5 mg) and Alpha Blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia.
- Trial name
- NCT05236634
- Testing
- Phosphodiesterase 5 Inhibitors, Alpha Blockers, Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
- Volunteers
- 120 people
- Sponsor
- Assiut University
Benign Prostatic Hypertrophy With Outflow Obstruction, Benign Prostatic Hyperplasia
Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia
Odyliresin (Iresine Celosia) is a cytochrome-flavoprotein with a powerful anti-oxydant action on cells, has a therapeutic effect on BPH-related LUTS, reducing symptoms, prostate volume, improving the patient's quality of life and…
- Trial name
- Odyliresin (NCT02977832)
- Testing
- Odyliresin, Alfuzosin
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.